63.57 USD
↗ 1.53 (2.47%)AT CLOSE (11:59 AM EDT)
Ionis Pharmaceuticals, Inc. Common Stock
IONSNASDAQ • USD
63.80
↗ 0.23 (0.36%)
POST MARKET (AS OF 07:49 PM EDT)
Post Market
AS OF 07:49 PM EDT
63.80
↗ 0.23 (0.36%)
Market: CLOSED
IONS is currently priced at $63.54. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, IONS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 25, 2026.
Open?$62.53
High?$64.19
Low?$62.19
Prev. Close?$62.04
Volume?2.4M
Avg. Volume?2.9M
VWAP?$63.58
Rel. Volume?0.84x
Bid / Ask
Bid?$60.18 × 100
Ask?$66.97 × 100
Spread?$6.79
Midpoint?$63.58
Valuation & Ratios
Market Cap?10.3B
Shares Out?166.2M
Float?162.8M
Float %?98.5%
P/E Ratio?N/A
P/B Ratio?23.45
EPS?-$3.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Themes
Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: (760) 931-9200
CARLSBAD, CA 92010
Phone: (760) 931-9200
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?23
Momentum?31
Short Sent.?54
Piotroski F-Score?2/9Weak
Altman Z-Score?1.60Distress
Confidence?73%Moderate
Short InterestHigh
Short % of Float?12.84%High
Short Interest?20.9M
Days to Cover?9.6
Free Float162.8M
Avg Daily Volume2.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?7.89Strong
Quick Ratio?7.73Strong
Cash Ratio?1.11Strong
Debt/Equity?3.01High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?23.45HIGH▾
Peers100
S&P3
P/S?11.80HIGH▾
Peers100
S&P6
P/FCF?N/A▾
EV/EBITDA?-19.4CHEAP▾
S&P97
EV/Sales?12.91HIGH▾
Peers100
S&P6
Returns & Efficiency
ROE?-128.5%WEAK▾
S&P3
ROA?-18.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-560839000
Enterprise Value?$11.3B
Fundamentals ratios updated end of day